You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
疫苗股榮辱互見 三葉草生物(02197.HK)急漲29%
世衛(WHO)總幹事譚德塞於世界衛生大會開幕致辭中強調,除非新冠疫情在全球各地都結束,否則在任何地方都不會結束。此外,猴痘疫情在全球多點爆發,至少14國出現逾180起確診及疑似病例,美國證實出現一宗確診個案,紐約市及佛羅里達州皆有疑似個案,正出訪亞洲的美國總統拜登指若疫情擴散,後果恐怕不堪設想,認為這是「每個人都該關注的問題」。 於本港上市的疫苗相關股今早以三葉草生物-B(02197.HK)表現最好,股價繼上周五整固後,今早升破20天線(4.46元),最高見5.13元,半日收4.99元,急漲29%,半日成交增至1,617萬股。 開拓藥業-B(09939.HK)高見24.6元,半日收23.65元,續升2.4%;騰盛博藥-B(02137.HK)高見9.06元,半日收8.81元,反覆續升1.1%:復星醫藥(02196.HK)連升兩天,最高見34.4元,半日收33.7元,續升0.6%。 然而,旗下疫苗上周獲世衛納入緊急使用單股價急漲一成康希諾生物-B(06185.HK)今早有兩手合共940萬股以每股70.5元(較上周五收市價折讓9.6%)非自動對盤上板,股價半日回吐9%曾低見70.5元。 國藥控股(01099.HK)反覆回吐0.9%半日收18.9元;歌禮-B(01672.HK)反覆回吐1.5%半日收3.94元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account